Janssen-Organized Standalone Meeting

Freedom from disease: Improving care for patients with psoriatic and rheumatological diseases

26–27 February 2021 and Workshops on Tuesdays to Thursday 2–17 March 2021

Scientific Committee

- Laura Coates; Rheumatologist (Co-Chair)
- Kilian Eyerich; Dermatologist (Co-Chair)
- Carlo Selmi; Rheumatologist (Co-Chair)
- Richard Warren; Dermatologist (Co-Chair)

Learning objectives

After this event, participants should be able to:

- Identify the interactions and common pathways across immune-mediated inflammatory diseases
- Describe the importance of early recognition of psoriatic diseases, and recognize the value of measuring disease activity to optimize management of these conditions
- Evaluate treatment targets and outcome measures for psoriasis and psoriatic arthritis
- Identify factors that influence treatment selection and management of patients with comorbidities
- Integrate the latest safety and efficacy clinical data, in addition to real-world data for the management of psoriasis and psoriatic arthritis
- Hypothesize how treatment optimization strategies could be utilized for optimal long-term patient outcomes

Friday 26 February (17:00-18:40 CET)

Session 1: Setting the scene [Chairs: Laura Coates, Richard Warren]

Time (CET)	Topic	Proposed speakers
17:00–17:05	Welcome & introduction	Laura Coates, Kilian Eyerich, Carlo
		Selmi, Richard Warren (SC)
17:05–17:20	Reshaping the future of immunology	Janssen
	 Advancing science for the benefit of patients 	
17:20–17:40	Highlights of Dermatology 2020	Richard Warren, Kilian Eyerich
17:40–18:00	Highlights of Rheumatology 2020	Laura Coates, Carlo Selmi
18:00–18:20	What have we learnt and where do we go next?	SC
	 How to treat patients in the digital era 	
	Round table discussion, audience Q&A	
18:20–18:40	Break	

Friday 26 February (18:40-20:00 CET)

Session 2 [Chairs: Laura Coates, Richard Warren]

Time (CET)	Topic	Proposed speakers
18:40-19:00	From the outside in: linking the skin, the joint, and the mind	Anthony Bewley
	 Touch on the emotional impact of the pandemic to 	
	patients and HCP	
	 Methods for better patient communication 	
	• Covers importance of patient-reported outcomes in	
	managing IMIDs	
19:00–19:10	Q & A	Carlo Selmi, Kilian Eyerich
19:10–19:40	That's Debateable:	Brian Kirby + Xenofon Baraliakos
	IL-23i vs IL-17i from derm and rheum perspective	vs Richard Warren + Laura Coates
	What will be your first switch?	Moderators: Kilian Eyerich,
	 Treat early and hard versus save the best for last 	William Tillet
19:40–19:50	Q & A	Laura Coates, Richard Warren
19:50-20:00	Summary of Day 1	SC
	 Include question for scoreboard + score check, 	
	polling question	

Saturday 27 February (09:30-11:00 CET)

Session 3: IL-23 takes centre stage [Chairs: Kilian Eyerich and Carlo Selmi]

Time (CET)	Topic	Proposed speakers
09:30-09:35	Welcome & introduction to day 2	SC
09:35-09:55	Linking pathophysiology to clinical options in IMIDs	Kilian Eyerich, Georg
		Schett
	Questions for scoreboard	
09:55-10:10	IL-23 pathway inhibition in psoriasis: what's new now	Richard Warren
	Questions for scoreboard	
10:10–10:25	IL-23 pathway inhibition in psoriatic arthritis: what's new	Carlo Selmi
	now	
	Questions for scoreboard	
10:25-10:45	Answering your burning questions	All faculty from this session
10:45-11:00	Break	
	 Virtual group photo 	

Saturday 27 February (11:00–13:15 CET)

Session 4 Clinical pearls: Parallel breakout sessions

Time (CET)	Topic	
11:00-11:45	Parallel sessions 1	
	Clinical pearls: regional psoriasis	Clinical pearls: enthesitis and dactylitis
	(Diamant Thaçi, Sasha Gerdes)	(James Galloway, Stefan Siebert)
	Parallel sessions 2	
11:45-12:30	Clinical pearls: specific populations in psoriasis	Clinical pearls: specific populations in PsA
	(Laura Savage, Andrew Pink)	(Dennis McGonagle, Richard Smith)
12:30-13:00	Lunch break	

Saturday 27 February (13:15–14:00 CET) Session 5 The future of disease management [Chairs: Carlo Selmi, Kilian Eyerich]

Time (CET)	Topic	Proposed speakers
13:00-13:20	Fantasy or reality? Towards understanding the TRM and disease modifying potential of IL-23 inhibitors Incorporate rheum perspective on disease modification	Kristian Reich
13:20–13:40	Tailoring the best long-term treatment management strategy for our patients	Laura Coates/Diamant Thaçi
13:40–13:55	 Fireside chat: visions of the future Panel discussion on the various topics such as future treatment landscape, patient management, hopes and promises on the future of medicine 	Laura Coates, Kilian Eyerich, Kristian Reich, Carlo Selmi, Diamant Thaçi
13:55–14:00	 Take home message and wrap up Scoreboard results Evaluation form leads to access to link to download certificate of attendance, access resources Resources e.g. clinical pearls, on-demand content (cannot be downloadable) 	Laura Coates, Kilian Eyerich, Carlo Selmi, Richard Warren

Daily clinical practice workshops for delegate selection (limited to 50 per workshop), 60 minutes: Tuesdays to Thursdays 2–17 March 2021

- 1. Holistic management of PsA Laura Savage and Laura Coates (4 Mar)
- 2. Personalized medicine in patients with IMIDs Alexander Egeberg and Laure Gossec (11 Mar)
- 3. Differential diagnosis of PsA Ennio Lubrano and Filip van den Bosch (3 Mar)
- 4. Psoriasis 101 for rheumatologists Andreas Pinter and Marc Radtke (10 Mar)
- 5. Managing comorbidities of patients with PsA Rubén Queiro and Ronald van Vollenhoven (17 Mar)
- 6. Managing comorbidities of patients with psoriasis Curdin Conrad and Jo Lambert (2 Mar)
- 7. PsA 101 for dermatologists Frank Behrens and Doug Veale (9 Mar)
- 8. Managing cardiovascular disease as a comorbidity Stefano Piaserico and Lluis Puig (16 Mar) Backup
- 9. Imaging update Eugenio de Miguel Mendieta and Xenofon Baraliakos
- 10. **Immunology 101 for rheumatologists and dermatologists** Dennis McGonagle and Andrea Chiricozzi